We invest across the full life sciences and healthcare spectrum, including biotechnology, diagnostics, digital health, medical devices, and chronic disease management.

Our primary focus is on companies in late-stage clinical development or the early phases of commercialization. In select cases, we also consider earlier-stage companies with truly breakthrough technologies that are backed by leading venture capital firms or strategic corporate partners.